HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy

Differences in rates, nature, and predictors

Robert K. Heaton, Donald R. Franklin, Ronald J. Ellis, J. Allen McCutchan, Scott L. Letendre, Shannon LeBlanc, Stephanie H. Corkran, Nichole A. Duarte, David B. Clifford, Steven P. Woods, Ann C. Collier, Christina M. Marra, Susan Morgello, Monica Rivera Mindt, Michael J. Taylor, Thomas D. Marcotte, J. Hampton Atkinson, Tanya Wolfson, Benjamin Gelman, Justin C. McArthur & 7 others David M. Simpson, Ian Abramson, Anthony Gamst, Christine Fennema-Notestine, Terry L. Jernigan, Joseph Wong, Igor Grant

Research output: Contribution to journalArticle

808 Citations (Scopus)

Abstract

Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV-) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV - participants from the pre-CART era (1988-1995; N=857) and CART era (2000-2007; N=937). Impairment rate increased with successive disease stages (CDC stages A, B, and C) in both eras: 25%, 42%, and 52% in pre-CART era and 36%, 40%, and 45% in CART era. In the medically asymptomatic stage (CDC-A), NCI was significantly more common in the. CART era. Low nadir CD4 predicted NCI in both eras, whereas degree of current immunosuppression, estimated duration of infection, and viral suppression in CSF (on treatment) were related to impairment only pre-CART. Pattern of NCI also differed: pre-CART had more impairment in motor skills, cognitive speed, and verbal fluency, whereas CART era involved more memory (learning) and executive function impairment. High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART. The consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND. Clinical trials targeting HAND prevention should specifically examine timing of ART initiation.

Original languageEnglish (US)
Pages (from-to)3-16
Number of pages14
JournalJournal of NeuroVirology
Volume17
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

HIV
Therapeutics
Neurocognitive Disorders
Centers for Disease Control and Prevention (U.S.)
Immunosuppression
HIV Infections
Motor Skills
Executive Function
Virus Diseases
Clinical Trials
Learning
Morbidity
Mortality

Keywords

  • Combination antiretroviral therapy
  • HIV
  • HIV dementia

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy : Differences in rates, nature, and predictors. / Heaton, Robert K.; Franklin, Donald R.; Ellis, Ronald J.; McCutchan, J. Allen; Letendre, Scott L.; LeBlanc, Shannon; Corkran, Stephanie H.; Duarte, Nichole A.; Clifford, David B.; Woods, Steven P.; Collier, Ann C.; Marra, Christina M.; Morgello, Susan; Rivera Mindt, Monica; Taylor, Michael J.; Marcotte, Thomas D.; Atkinson, J. Hampton; Wolfson, Tanya; Gelman, Benjamin; McArthur, Justin C.; Simpson, David M.; Abramson, Ian; Gamst, Anthony; Fennema-Notestine, Christine; Jernigan, Terry L.; Wong, Joseph; Grant, Igor.

In: Journal of NeuroVirology, Vol. 17, No. 1, 02.2011, p. 3-16.

Research output: Contribution to journalArticle

Heaton, RK, Franklin, DR, Ellis, RJ, McCutchan, JA, Letendre, SL, LeBlanc, S, Corkran, SH, Duarte, NA, Clifford, DB, Woods, SP, Collier, AC, Marra, CM, Morgello, S, Rivera Mindt, M, Taylor, MJ, Marcotte, TD, Atkinson, JH, Wolfson, T, Gelman, B, McArthur, JC, Simpson, DM, Abramson, I, Gamst, A, Fennema-Notestine, C, Jernigan, TL, Wong, J & Grant, I 2011, 'HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors', Journal of NeuroVirology, vol. 17, no. 1, pp. 3-16. https://doi.org/10.1007/s13365-010-0006-1
Heaton, Robert K. ; Franklin, Donald R. ; Ellis, Ronald J. ; McCutchan, J. Allen ; Letendre, Scott L. ; LeBlanc, Shannon ; Corkran, Stephanie H. ; Duarte, Nichole A. ; Clifford, David B. ; Woods, Steven P. ; Collier, Ann C. ; Marra, Christina M. ; Morgello, Susan ; Rivera Mindt, Monica ; Taylor, Michael J. ; Marcotte, Thomas D. ; Atkinson, J. Hampton ; Wolfson, Tanya ; Gelman, Benjamin ; McArthur, Justin C. ; Simpson, David M. ; Abramson, Ian ; Gamst, Anthony ; Fennema-Notestine, Christine ; Jernigan, Terry L. ; Wong, Joseph ; Grant, Igor. / HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy : Differences in rates, nature, and predictors. In: Journal of NeuroVirology. 2011 ; Vol. 17, No. 1. pp. 3-16.
@article{079551e292724d92be2118ff9136ca49,
title = "HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors",
abstract = "Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV-) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV - participants from the pre-CART era (1988-1995; N=857) and CART era (2000-2007; N=937). Impairment rate increased with successive disease stages (CDC stages A, B, and C) in both eras: 25{\%}, 42{\%}, and 52{\%} in pre-CART era and 36{\%}, 40{\%}, and 45{\%} in CART era. In the medically asymptomatic stage (CDC-A), NCI was significantly more common in the. CART era. Low nadir CD4 predicted NCI in both eras, whereas degree of current immunosuppression, estimated duration of infection, and viral suppression in CSF (on treatment) were related to impairment only pre-CART. Pattern of NCI also differed: pre-CART had more impairment in motor skills, cognitive speed, and verbal fluency, whereas CART era involved more memory (learning) and executive function impairment. High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART. The consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND. Clinical trials targeting HAND prevention should specifically examine timing of ART initiation.",
keywords = "Combination antiretroviral therapy, HIV, HIV dementia",
author = "Heaton, {Robert K.} and Franklin, {Donald R.} and Ellis, {Ronald J.} and McCutchan, {J. Allen} and Letendre, {Scott L.} and Shannon LeBlanc and Corkran, {Stephanie H.} and Duarte, {Nichole A.} and Clifford, {David B.} and Woods, {Steven P.} and Collier, {Ann C.} and Marra, {Christina M.} and Susan Morgello and {Rivera Mindt}, Monica and Taylor, {Michael J.} and Marcotte, {Thomas D.} and Atkinson, {J. Hampton} and Tanya Wolfson and Benjamin Gelman and McArthur, {Justin C.} and Simpson, {David M.} and Ian Abramson and Anthony Gamst and Christine Fennema-Notestine and Jernigan, {Terry L.} and Joseph Wong and Igor Grant",
year = "2011",
month = "2",
doi = "10.1007/s13365-010-0006-1",
language = "English (US)",
volume = "17",
pages = "3--16",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy

T2 - Differences in rates, nature, and predictors

AU - Heaton, Robert K.

AU - Franklin, Donald R.

AU - Ellis, Ronald J.

AU - McCutchan, J. Allen

AU - Letendre, Scott L.

AU - LeBlanc, Shannon

AU - Corkran, Stephanie H.

AU - Duarte, Nichole A.

AU - Clifford, David B.

AU - Woods, Steven P.

AU - Collier, Ann C.

AU - Marra, Christina M.

AU - Morgello, Susan

AU - Rivera Mindt, Monica

AU - Taylor, Michael J.

AU - Marcotte, Thomas D.

AU - Atkinson, J. Hampton

AU - Wolfson, Tanya

AU - Gelman, Benjamin

AU - McArthur, Justin C.

AU - Simpson, David M.

AU - Abramson, Ian

AU - Gamst, Anthony

AU - Fennema-Notestine, Christine

AU - Jernigan, Terry L.

AU - Wong, Joseph

AU - Grant, Igor

PY - 2011/2

Y1 - 2011/2

N2 - Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV-) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV - participants from the pre-CART era (1988-1995; N=857) and CART era (2000-2007; N=937). Impairment rate increased with successive disease stages (CDC stages A, B, and C) in both eras: 25%, 42%, and 52% in pre-CART era and 36%, 40%, and 45% in CART era. In the medically asymptomatic stage (CDC-A), NCI was significantly more common in the. CART era. Low nadir CD4 predicted NCI in both eras, whereas degree of current immunosuppression, estimated duration of infection, and viral suppression in CSF (on treatment) were related to impairment only pre-CART. Pattern of NCI also differed: pre-CART had more impairment in motor skills, cognitive speed, and verbal fluency, whereas CART era involved more memory (learning) and executive function impairment. High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART. The consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND. Clinical trials targeting HAND prevention should specifically examine timing of ART initiation.

AB - Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV-) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV - participants from the pre-CART era (1988-1995; N=857) and CART era (2000-2007; N=937). Impairment rate increased with successive disease stages (CDC stages A, B, and C) in both eras: 25%, 42%, and 52% in pre-CART era and 36%, 40%, and 45% in CART era. In the medically asymptomatic stage (CDC-A), NCI was significantly more common in the. CART era. Low nadir CD4 predicted NCI in both eras, whereas degree of current immunosuppression, estimated duration of infection, and viral suppression in CSF (on treatment) were related to impairment only pre-CART. Pattern of NCI also differed: pre-CART had more impairment in motor skills, cognitive speed, and verbal fluency, whereas CART era involved more memory (learning) and executive function impairment. High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART. The consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND. Clinical trials targeting HAND prevention should specifically examine timing of ART initiation.

KW - Combination antiretroviral therapy

KW - HIV

KW - HIV dementia

UR - http://www.scopus.com/inward/record.url?scp=79952921819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952921819&partnerID=8YFLogxK

U2 - 10.1007/s13365-010-0006-1

DO - 10.1007/s13365-010-0006-1

M3 - Article

VL - 17

SP - 3

EP - 16

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 1

ER -